The incorporation of artificial intelligence into clinical practices has transformed from being an innovative idea into a key factor that drives modern healthcare systems. Tempus AI, Inc. made headlines with its recent launch of ArteraAI Prostate Test for the purpose of determining the likelihood of a patient dying from prostate cancer when dealing with a diagnosis of metastatic hormone-sensitive prostate cancer (mHSPC). ArteraAI represents a fully digitized pathology test that is available via the Tempus system, representing the first-time clearance of an external pathology algorithm on the company’s platform.
The algorithm generates the risk score using the personal clinical data of the individual, along with the digital image of the tissue biopsy that the patient undergoes, to determine the risks associated with the development of prostate cancer and death from such a condition within the context of personal likelihoods. The above is especially important since there are an estimated 25,000 new cases of metastatic prostate cancer that occur annually in the US. Clinical experts may also use their own evaluation while using ArteraAI in combination with NGS genomics by Tempus.
This is not only an immediate win for oncologists and patient health, but also an impending revolution for the life sciences industry.
Accelerating the Convergence of Multimodal Data
In the life sciences industry, the trend for years has been to work within distinct silos. Genomics enterprises focused on genomic sequencing, whereas pathology services focused on the stained tissues on the glass slides. The collaboration between Tempus and Artera exemplifies the emerging shift towards using multiple modalities in diagnostics, whereby several data sources, such as clinical notes, genetics, and images, combine to provide an all-encompassing diagnostic test.
The takeaway message for life science enterprises in the market is that single-modal diagnostics are now out of favor. Firms that base their business model on single-modal tests risk becoming irrelevant. In order to be successful and relevant, life sciences developers need to construct or even purchase an all-in-one diagnostic platform. The shift here is from a business model focused on producing lab data to one based on instant clinical knowledge.
Also Read: Charles River Advances AI-Driven Digital Pathology to Accelerate Drug Research
Rewriting the Commercialization Blueprint: Ecosystem Playbooks
Some of the key strategic lessons we learn from this announcement include how the news changes the dynamics for the commercialization process in the biotech space. While developing a novel clinical algorithm is one thing, distributing the products commercially, managing laboratory logistics and EHR integration processes are all massive expenses.
As a platform that will host the ecosystem, Tempus offers Artera the ability to quickly distribute its algorithm among an already present network of urologists and oncologists who order the solid tumor panel by Tempus. The “Ecosystem-as-a-Service” strategy is something seen in app stores in the tech industry. In the world of life sciences and digital health start-ups, this creates a new play book for entering markets. Newer companies can invest less money in building out separate sales channels and focus on validation, while leveraging diagnostic platforms for distribution. Incumbent companies, on the other hand, need to adapt into ecosystem orchestrators and make room on their platforms for third-party algorithms.
Elevating Clinical Trial Efficiency and Drug Discovery
However, in addition to use for diagnosis, the growing prevalence of instruments such as the ArteraAI Prostate Test also exerts a significant downstream effect on the life sciences industry through its pharmaceutical companies and CROs. The problem of expensive, inefficient clinical trials remains a perpetual challenge within this field. Precision clinical trials based on exact risk stratification significantly increase the likelihood of success.
By providing greater accuracy in digital pathology data, drug companies can determine specifically which subgroups react to various drugs. Thus, the size of clinical trials is reduced, as are the expenses associated with the process, making the development faster and more efficient.
Facing the Regulated Future
Certainly, the use of AI within the life sciences ecosystem does come with certain difficulties, especially with regard to issues of data protection and the changing compliance environment. With increasing use of AI in digital pathology, the FDA, CLIA, and CAP are constantly working on updating compliance standards for AI diagnostics. The life sciences companies need to make sure that they have a good data security architecture and compliance team.
The Bottom Line
The launch of the ArteraAI test using the Tempus platform is far from just a launch event; instead, it can be considered an emblem of the next step in the evolution of the life sciences industry. In this age of change, those who succeed will be companies that go beyond conventional frameworks, adopting collaborative networks, data aggregation, and AI-based solutions. Through the use of AI technologies to make sense of diagnoses, the industry is extending human life expectancy limits.
